If the agency approves its application, the firm will begin a Phase I clinical trial in c-MYC-driven cancers in 2026.

UTR Therapeutics Inc. has submitted an IND application to the FDA for UTRxM1-18, a novel therapeutic approach for targeting c-MYC-driven cancers. Pending approval, a first-in-human phase I trial is ...

Most research into Myc has focused on expression at the mRNA level, but that might not be the most effective way, Ruggero said. “How much transcription Myc you have, it doesn’t mean much ...